2025-09-16
Colorado, USA–September 2025–Duob Investment Co., Ltd. (“DUOB”), a leading U.S.-based AI robotics company, today announced its financial results for the second quarter of fiscal year 2025, ended June 30, 2025. The report shows total revenue of $810 million, representing a 38% year-over-year increase, and net profit of $140 million, marking a 62% increase compared to the same period last year. These results far exceeded market expectations and further solidified DUOB’s leadership position in the global AI robotics industry.
The company attributed its strong growth to the continued expansion of its global gaming equipment AI robotics business segment. DUOB noted particularly strong demand in North American and Asian markets, which significantly contributed to overall revenue and profitability growth.
Looking ahead, DUOB plans to deepen its global market presence, with a strong focus on Asia, Europe, and emerging markets. The company will continue pursuing its“technology innovation + market expansion”dual-engine strategy to sustain high-quality growth while expanding AI robotics applications across a broader range of industries.
In addition, DUOB emphasized its commitment to philanthropy and social impact initiatives. The company is actively investing in the innovative use of AI technologies in charitable endeavors. Through its“Technology for Good”approach, DUOB aims to make artificial intelligence a truly inclusive force driving societal progress.
Company: Duob Investment Co., Ltd.
Contact Person:Mark
Facebook:https://www.facebook.com/share/g/1CZo2v7vLA/
Website: https://duob.top/about/
Telephone:+13038238310
City:Colorado, USA
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
MEXC Claims Dual Wins at BeInCrypto 100 Awards as Best Centralized Exchange and Best Exchange in LATAM
©copyright2009-2020Fresh life